RecruitingPhase 3NCT06049901

Nitazoxanide in Patients With Metastatic Colorectal Cancer

Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Patients With Metastatic Colorectal Cancer


Sponsor

Tanta University

Enrollment

60 participants

Start Date

Mar 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to evaluate the potential efficacy and safety of nitazoxanide in patients with metastatic colorectal cancer.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether an anti-parasitic drug called nitazoxanide can help treat colorectal cancer that has spread to other organs (metastatic). Researchers believe the drug may have anti-cancer properties in addition to its known uses. **You may be eligible if...** - You have been diagnosed with stage IV (metastatic) colorectal cancer confirmed by biopsy - You are between 18 and 65 years old - You are in reasonably good overall health - Your liver is functioning adequately - Women of childbearing age must use contraception **You may NOT be eligible if...** - You have conditions that prevent you from safely receiving chemotherapy - Your liver function is significantly impaired - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNitazoxanide

Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.


Locations(1)

Tanta University Hospital

Tanta, El-Gharbia Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06049901


Related Trials